Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival

Pelkonen, Mikko; Luostari, Kaisa; Tengström, Maria; Ahonen, Hermanni; Berdel, Bozena; Kataja, Vesa; Soini, Ylermi; Kosma, Veli-Matti; Mannermaa, Arto

doi:10.1186/s12885-015-1440-5

BMC Cancer

Table 1 Clinicopathological charasteristics of the patients

From: Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival

	Cases in TMPRSS1		Cases in TMPRSS3		Cases in TMPRSS1*		Cases in TMPRSS3
	mRNA expression		mRNA expression		protein expression		protein expression
Clinical variable	n	%	n	%	n	%	n	%
Breast tumor samples
Malignant	125	88.7	167	87.9	372	100	373	100
Benign	16	11.3	23	12.1
Histological type
Ductal	89	63.2	118	62.1	236	63.5	237	63.5
Lobular	20	14.2	31	16.3	73	19.6	72	19.3
Other malignant	16	11.3	18	9.5	63	16.9	64	17.2
Benign	16	11.3	23	12.1
Age at diagnosis
< = 39	12	9.6	14	8.4	31	8.3	31	8.3
40–49	22	17.6	29	17.4	91	24.5	91	24.4
50–59	29	23.2	38	22.8	88	23.7	88	23.6
60–69	18	14.4	28	16.7	53	14.2	54	14.5
> = 70	44	35.2	58	34.7	109	29.3	109	29.2
Tumor grade
I	24	19.2	28	16.8	87	23.4	88	23.6
II	51	40.8	74	44.3	162	43.6	161	43.2
III	48	38.4	60	35.9	105	28.2	106	28.4
NA	2	1.6	5	3.0	18	4.8	18	4.8
Tumor size
T1	46	36.8	63	37.7	173	46.5	174	46.6
T2	64	51.2	84	50.3	160	43.0	160	42.9
T3	9	7.2	12	7.2	19	5.1	20	5.4
T4	6	4.8	8	4.8	15	4.0	15	4.0
NA					5	1.4	4	1.1
Nodal status
Negative	71	56.8	87	52.1	197	53.0	198	53.1
Positive	51	40.8	73	43.7	155	41.6	155	41.5
NA	3	2.4	7	4.2	20	5.4	20	5.4
Stage
I	34	27.2	42	25.1	121	32.5	122	32.7
II	74	59.2	97	58.1	184	49.5	184	49.3
III	10	8.0	14	8.4	32	8.6	32	8.6
IV	4	3.2	7	4.2	13	3.5	13	3.5
NA	3	2.4	7	4.2	22	5.9	22	5.9
ER status
Negative	40	32.0	50	29.9	82	22.0	83	22.2
Positive	83	66.4	111	66.5	270	72.6	270	72.4
NA	2	1.6	6	3.6	20	5.4	20	5.4
PR status
Negative	56	44.8	70	41.9	140	37.6	141	37.8
Positive	67	53.6	91	54.5	212	57.0	211	56.6
NA	2	1.6	6	3.6	20	5.4	21	5.6
HER2 status
Negative	99	79.2	130	77.8	299	80.4	299	80.2
Positive	19	15.2	24	14.4	46	12.3	46	12.3
NA	7	5.6	13	7.8	27	7.3	28	7.5
ER/PR/HER2 status
Triple-negative	24	19.2	29	17.4	42	11.3	43	11.5
Non-triple-negative	94	75.2	122	73.0	289	77.7	288	77.2
NA	7	5.6	16	9.6	41	11.0	42	11.3
Radiotherapy
Yes	66	52.8	84	50.3	205	55.1	208	55.8
No	59	47.2	83	49.7	167	44.9	165	44.2
Chemotherapy
Yes	18	14.4	26	15.6	69	18.5	69	18.5
No	107	85.6	141	84.4	303	81.5	304	81.5
Tamoxifen
Yes	23	18.4	31	18.6	62	16.7	62	16.6
No	102	81.6	136	81.4	310	83.3	311	83.4
Latest follow-up status
Alive	38	30.4	52	31.2	149	40.1	149	39.9
Died of breast cancer	42	33.6	56	33.5	112	30.1	113	30.3
Died of other reason	45	36.0	59	35.3	111	29.8	111	29.8

NA, data not avalaible; *hepsin

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com